Support us | Visit us | Contact us
The Royal Society Enterprise Fund is a new initiative aimed at providing equity finance and other support to start up companies with outstanding commercial potential founded on excellent science and technology.
Introduction to the Enterprise Fund (5 mins).
Uniquely, the fund is financed by philanthropy and is designed to be evergreen, with all financial returns recycled into the fund to support future investments.
The operation of the fund builds on the strength and breadth of the Royal Society network of Fellows, Research Fellows and other relationships. As well as providing a continuing high-quality flow of investment opportunities, these networks support the fund with due diligence and other important advice.
The objective for the Royal Society Enterprise Fund is to become a financially successful contributor to early stage company support and a role model for the translation of excellent science for commercial and social benefit.
Since 2008 the management team has led the investment in a portfolio of five companies. We are interested in receiving proposals for funding from innovative early-stage technology companies that have strong prospects for growth.
Enterprise Fund portfolio company keeps human liver alive outside body (15 Mar 2013)Over a decade of research by Oxford University academics leads to the world’s first liver transplant using a liver kept alive and functioning on a machine outside the patient’s body. This device is being commercialised by Royal Society Enterprise Fund portfolio company, OrganOx.
Royal Society Enterprise Fund portfolio company Sphere Fluidics closes £1.6 million investment round (01 Mar 2013)Sphere Fluidics, an early-stage, Cambridge-based company focussing on developing novel products and services for single cell analysis, has just completed a £1.6 million investment round.
Enterprise Fund backs liver technology (08 Feb 2011)The Royal Society Enterprise Fund has participated in a £2.75m funding round for OrganOx Ltd which is developing a medical device that will significantly increase the number of human livers available for transplant.
Royal Society invests further in Novacem (28 Jan 2011)The Royal Society Enterprise Fund announced this week that it has participated in a £1.6m funding round for Novacem, a company developing carbon negative cement.
Miniature droplet technology receives Royal Society Enterprise Fund backing (18 Nov 2010)The Royal Society Enterprise Fund has led an investment syndicate backing Cambridge-based company, Sphere Fluidics. The University of Cambridge spin-out is working on miniature droplet technology which will allow for the rapid identification, analysis and separation of single cells and molecules.
See the news archive for the Royal Society Enterprise Fund here.
Email: Write to: The Royal Society Enterprise Fund, The Royal Society, 6-9 Carlton House Terrace, London SW1Y 5AG
Learn about our mission to expand the frontiers of knowledge.
There are about 1,450 Fellows and Foreign Members.
The Council and Board manage the Society's activities.
We have had 350 years at the heart of scientific progress.
Annual publications about our finances and activities.
Information about jobs and internships at the Royal Society.